Filters Applied:
Patients say the pharmaceutical companies failed to warn them of a risk of a rare condition that causes vision loss.
| Keywords | glp-1pharmaceuticalsmedicinehealthcareozempicweight-lossbig-pharmahealthside-effectsmedicationobesitywegovydiabetesdrug-safetyhealth-risksobesity-medicationzepboundlawsuitlegalvision-loss |
GLP-1s have increasingly gained prominence in recent years as effective weight-loss drugs.
| Keywords | jb-pritzkerglp-1weight-lossillinoishealthmedicineozempicobesityhealthcaremedicationdiabeteslifestyle-drugsbiotechnologybig-pharmawegovyzepboundmounjarowellnessmedical-news |
Illinois Gov. JB Pritzker (D) revealed Monday on “CBS Mornings” that he has been taking a GLP-1 medication since he was diagnosed with diabetes two years ago.
| Keywords | glp-1weight-losshealthdiabetesjb-pritzkerillinoismedicinemedicationsemaglutideozempicwegovyzepboundbig-pharmahealthcarelifestyle-drugsmedical-newspublic-healthwellness |
For those who rely on the medications, the difference between health plans that cover them and those that don't can mean hundreds of dollars a month.
Dr. Anil Shah says patients should try to map out a healthy diet and exercise routine before turning to injections for weight loss.
Experts say there isn't enough evidence to prove weight-loss drugs are the sole reason retailers are reducing larger sizes.
Luxury wellness retreats are being designed around people who use or are considering medications such as Ozempic, Wegovy, Mounjaro and Zepbound. Think sunrise yoga, protein-focused meals, strength training and life coaching, all for $12,000 a week. On Thursday's “Hot Take with Jesse Weber,” we break down whether these retreats provide the long-term support GLP-1 users need or whether the luxury wellness industry has found its next expensive cash cow. We'll also examine why GLP-1 use has nearly quadrupled in the past two years. Then, we're joined by Jill Boyd, COO of Hilton Head Health, one of the resorts now offering a specialized GLP-1 experience, to discuss the cost, medical oversight and value.
Medicare's first-of-its-kind weight-loss drug program has officially launched, giving American seniors access to GLP-1 drugs at a subsidized cost.
Medicare’s new weight-loss drug program offers affordable access to GLP-1 medication for seniors, marking a significant shift in healthcare coverage and efforts to combat obesity . PULSE POINTS WHAT HAPPENED: Medicare’s first-of-its-kind weight-loss drug program has officially launched, giving American seniors access to GLP-1 drugs at a subsidized cost. DETAIL: On Wednesday, Medicare & Medicaid Services launched a new program allowing Americans aged 65 and older to access weight-loss drugs at a reduced cost of $50 a month, starting with an 18-month trial period. This is the first time Medicare has offered coverage for GLP-1 weight-loss drugs, such as Novo Nordisk’s Wegovy and Eli Lilly’s Foundayo and Zepbound. Previously, Medicare…Open
A Medicare pilot beginning Wednesday will broaden access to medications like Wegovy and Zepbound. There are unique risks for those over 65.
| Keywords | glp-1medicarewegovyzepboundhealthmedicineobesityweight-lossdiabeteshealthcaremedical-newsseniorsolder-adultsmedicationaccesspublic-healthclinical-studytreatmentnytimescoverage |
Could GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound be far more than weight-loss drugs? In this special bonus episode of Greta Wire, Greta Van Susteren is joined by Dr. Jen Ashton on NEWSMAX TV’s The Record with Greta Van Susteren to discuss a new study suggesting GLP-1 drugs may be associated with reduced cancer progression in several obesity-related cancers. Dr. Ashton explains what the study found, what it does — and does not — prove, and why researchers are now looking at GLP-1 medications for possible effects on inflammation, the immune system, cancer spread, recurrence, and prevention. Greta also presses on the insurance question: if these drugs may help prevent expensive and devastating medical complications,…